| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013.
|
Lancet
|
2015
|
7.99
|
|
2
|
Global, regional, and national disability-adjusted life years (DALYs) for 306 diseases and injuries and healthy life expectancy (HALE) for 188 countries, 1990-2013: quantifying the epidemiological transition.
|
Lancet
|
2015
|
6.13
|
|
3
|
Health Effects of Overweight and Obesity in 195 Countries over 25 Years.
|
N Engl J Med
|
2017
|
3.90
|
|
4
|
The impact of resection margin status and postoperative CA19-9 levels on survival and patterns of recurrence after postoperative high-dose radiotherapy with 5-FU-based concurrent chemotherapy for resectable pancreatic cancer.
|
Am J Clin Oncol
|
2008
|
1.67
|
|
5
|
Estimates of global, regional, and national incidence, prevalence, and mortality of HIV, 1980-2015: the Global Burden of Disease Study 2015.
|
Lancet HIV
|
2016
|
1.51
|
|
6
|
Multicenter results of stereotactic body radiotherapy (SBRT) for non-resectable primary liver tumors.
|
Acta Oncol
|
2012
|
1.06
|
|
7
|
Dynamics of glutathione and ophthalmate traced with 2H-enriched body water in rats and humans.
|
Am J Physiol Endocrinol Metab
|
2009
|
1.05
|
|
8
|
Stereotactic body radiation therapy for nonresectable tumors of the pancreas.
|
J Surg Res
|
2011
|
0.97
|
|
9
|
Polyethylene glycol modified-albumin enhances the cold preservation properties of University of Wisconsin solution in rat liver and a hepatocyte cell line.
|
J Surg Res
|
2009
|
0.92
|
|
10
|
Emerging role of stereotactic body radiotherapy in the treatment of pancreatic cancer.
|
Expert Rev Anticancer Ther
|
2013
|
0.81
|
|
11
|
Early experience with intraoperative radiotherapy in patients with resected pancreatic adenocarcinoma.
|
Am J Surg
|
2008
|
0.76
|
|
12
|
Loco-regional therapy in patients with Milan Criteria-compliant hepatocellular carcinoma and short waitlist time to transplant: an outcome analysis.
|
HPB (Oxford)
|
2012
|
0.75
|